Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intermediate dose recombinant interferon-alpha as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon.
Ascierto PA, Daponte A, Parasole R, Perrone F, Caracò C, Melucci M, Palmieri G, Napolitano M, Mozzillo N, Castello G. Ascierto PA, et al. Among authors: mozzillo n. Cancer. 2000 Oct 1;89(7):1490-4. doi: 10.1002/1097-0142(20001001)89:7<1490::aid-cncr11>3.0.co;2-v. Cancer. 2000. PMID: 11013362 Clinical Trial.
Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA, Napolitano M, Celentano E, Simeone E, Gentilcore G, Daponte A, Capone M, Caracò C, Calemma R, Beneduce G, Cerrone M, De Rosa V, Palmieri G, Castello G, Kirkwood JM, Marincola FM, Mozzillo N. Ascierto PA, et al. Among authors: mozzillo n. J Transl Med. 2010 Aug 16;8:76. doi: 10.1186/1479-5876-8-76. J Transl Med. 2010. PMID: 20712892 Free PMC article. Clinical Trial.
Update on PEG-interferon α-2b as adjuvant therapy in melanoma.
Di Trolio R, Simeone E, Di Lorenzo G, Grimaldi AM, Romano A, Ayala F, Caracò C, Mozzillo N, Ascierto PA. Di Trolio R, et al. Among authors: mozzillo n. Anticancer Res. 2012 Sep;32(9):3901-9. Anticancer Res. 2012. PMID: 22993335 Review.
Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma.
Daponte A, Signoriello S, Maiorino L, Massidda B, Simeone E, Grimaldi AM, Caracò C, Palmieri G, Cossu A, Botti G, Petrillo A, Lastoria S, Cavalcanti E, Aprea P, Mozzillo N, Gallo C, Comella G, Ascierto PA; Southern Italy Cooperative Oncology Group (SICOG). Daponte A, et al. Among authors: mozzillo n. J Transl Med. 2013 Feb 13;11:38. doi: 10.1186/1479-5876-11-38. J Transl Med. 2013. PMID: 23402397 Free PMC article. Clinical Trial.
154 results